ANIP insider transaction filings
ANI PHARMACEUTICALS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-13. Screen ANIP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Sale (S): 500 @ $75.48 | EDGAR |
| 2026-08-11 | 4 | Gutwerg Ori — SVP, GENERICS | Sale (S): 3,162 @ $77 | EDGAR |
| 2026-07-30 | 4 | CAREY STEPHEN P. — SVP & CFO | Sale (S): 2,850 @ $81.36 | EDGAR |
| 2026-07-21 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Tax withholding (F): 2,466 @ $79.20 | EDGAR |
| 2026-07-14 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Sale (S): 500 @ $81.84 | EDGAR |
| 2026-07-06 | 4 | CAREY STEPHEN P. — SVP & CFO | Option exercise (M): 3,313 @ $49.51 · Sale (S): 3,313 @ $86 · Option exercise (M): 3,313 (derivative) @ $49.51 | EDGAR |
| 2026-06-30 | 4 | CAREY STEPHEN P. — SVP & CFO | Sale (S): 2,850 @ $84.12 | EDGAR |
| 2026-06-15 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Sale (S): 500 @ $82.03 | EDGAR |
| 2026-06-10 | 4 | Thoma Jeanne — Director | Grant/award (A): 4,357 @ $0 | EDGAR |
| 2026-06-10 | 4 | Leonard Matthew J — Director | Grant/award (A): 4,357 @ $0 | EDGAR |
| 2026-06-10 | 4 | Pera Antonio R — Director | Grant/award (A): 4,357 @ $0 | EDGAR |
| 2026-06-10 | 4 | TANNENBAUM RENEE P — Director | Grant/award (A): 4,357 @ $0 | EDGAR |
| 2026-06-10 | 4 | HAUGHEY THOMAS — Director | Grant/award (A): 4,357 @ $0 · Sale (S): 2,000 @ $80.88 | EDGAR |
| 2026-06-09 | 4 | CAREY STEPHEN P. — SVP & CFO | Option exercise (M): 3,312 @ $49.51 · Sale (S): 3,312 @ $80 · Option exercise (M): 3,312 (derivative) @ $49.51 | EDGAR |
| 2026-05-13 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Sale (S): 500 @ $78.16 | EDGAR |
| 2026-05-13 | 4 | Gutwerg Ori — SVP, GENERICS | Sale (S): 2,772 @ $79.50 | EDGAR |
| 2026-05-13 | 4 | Lalwani Nikhil — PRESIDENT & CEO, Director | Sale (S): 55,000 @ $77.57 | EDGAR |
| 2026-05-13 | 4 | Walsh Patrick D — Director | Sale (S): 3,973 @ $80.75 · Sale (S): 10,000 @ $80.63 | EDGAR |
| 2026-05-13 | 4 | Rowland Thomas Andrew — SVP, HEAD - ESTABLISHED BRANDS | Sale (S): 459 @ $79.21 | EDGAR |
| 2026-04-13 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Sale (S): 500 @ $77.95 | EDGAR |
| 2026-03-13 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Sale (S): 500 @ $72.62 | EDGAR |
| 2026-03-13 | 4 | Mutz Christopher — HEAD OF RARE DISEASE | Sale (S): 3,162 @ $71.64 | EDGAR |
| 2026-03-13 | 4 | Rowland Thomas Andrew — SVP, HEAD - ESTABLISHED BRANDS | Sale (S): 4,772 @ $74.91 | EDGAR |
| 2026-03-10 | 4 | Davis Krista — SVP, CHIEF HR OFFICER | Sale (S): 1,485 @ $75 · Sale (S): 5,087 @ $74.13 | EDGAR |
| 2026-03-10 | 4 | Mutz Christopher — HEAD OF RARE DISEASE | Sale (S): 2,121 @ $74.22 · Tax withholding (F): 3,314 @ $74.04 · Sale (S): 3,602 @ $74.18 | EDGAR |
| 2026-03-10 | 4 | Gutwerg Ori — SVP, GENERICS | Tax withholding (F): 3,314 @ $74.04 | EDGAR |
| 2026-03-10 | 4 | Lalwani Nikhil — PRESIDENT & CEO, Director | Tax withholding (F): 17,060 @ $74.04 | EDGAR |
| 2026-03-10 | 4 | CAREY STEPHEN P. — SVP & CFO | Tax withholding (F): 5,150 @ $74.04 | EDGAR |
| 2026-03-05 | 4 | CAREY STEPHEN P. — SVP & CFO | Option exercise (M): 3,312 @ $49.51 · Sale (S): 3,312 @ $75.42 · Sale (S): 4,000 @ $75.56 · Option exercise (M): 3,312 (derivative) @ $49.51 | EDGAR |
| 2026-03-04 | 4 | Mutz Christopher — HEAD OF RARE DISEASE | Sale (S): 417 @ $74 | EDGAR |
| 2026-03-04 | 4 | Gutwerg Ori — SVP, GENERICS | Sale (S): 2,060 @ $76.50 | EDGAR |
| 2026-03-03 | 4 | Walsh Patrick D — Director | Sale (S): 6,000 @ $74.23 | EDGAR |
| 2026-03-02 | 4 | Davis Krista — SVP, CHIEF HR OFFICER | Grant/award (A): 10,810 @ $77.15 · Tax withholding (F): 1,555 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Grant/award (A): 13,895 @ $77.15 · Tax withholding (F): 1,555 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | Gassert Chad — SVP - CORP. DEV. & STRATEGY | Grant/award (A): 11,116 @ $77.15 · Tax withholding (F): 2,221 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | Shanmugam Muthusamy — HEAD OF R&D, COO-NOVITIUM OPS, Director | Grant/award (A): 11,116 @ $77.15 | EDGAR |
| 2026-03-02 | 4 | Mutz Christopher — HEAD OF RARE DISEASE | Grant/award (A): 21,306 @ $77.15 · Tax withholding (F): 2,221 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | Gutwerg Ori — SVP, GENERICS | Grant/award (A): 12,969 @ $77.15 · Tax withholding (F): 2,221 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | Lalwani Nikhil — PRESIDENT & CEO, Director | Grant/award (A): 75,592 @ $77.15 · Tax withholding (F): 12,217 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | CAREY STEPHEN P. — SVP & CFO | Grant/award (A): 22,233 @ $77.15 · Tax withholding (F): 2,773 @ $73.90 | EDGAR |
| 2026-03-02 | 4 | Rowland Thomas Andrew — SVP, HEAD - ESTABLISHED BRANDS | Grant/award (A): 6,021 @ $77.15 · Tax withholding (F): 628 @ $73.90 | EDGAR |
| 2026-02-23 | 4 | Davis Krista — SVP, CHIEF HR OFFICER | Sale (S): 2,084 @ $77.53 · Sale (S): 1,730 @ $77.99 | EDGAR |
| 2026-02-23 | 4 | Mutz Christopher — HEAD OF RARE DISEASE | Sale (S): 5,323 @ $78.02 | EDGAR |
| 2026-02-17 | 4 | Davis Krista — SVP, CHIEF HR OFFICER | Tax withholding (F): 1,180 @ $76.70 · Tax withholding (F): 1,290 @ $77.36 | EDGAR |
| 2026-02-17 | 4 | Cook Meredith — SR. VP, GENERAL COUNSEL & SEC. | Tax withholding (F): 1,534 @ $76.70 · Sale (S): 500 @ $76.80 · Tax withholding (F): 1,779 @ $77.36 | EDGAR |
| 2026-02-17 | 4 | Gassert Chad — SVP - CORP. DEV. & STRATEGY | Tax withholding (F): 1,608 @ $76.70 · Tax withholding (F): 1,717 @ $77.36 | EDGAR |
| 2026-02-17 | 4 | Mutz Christopher — HEAD OF RARE DISEASE | Tax withholding (F): 3,173 @ $76.70 · Sale (S): 7,032 @ $76.55 · Tax withholding (F): 2,403 @ $77.36 | EDGAR |
| 2026-02-17 | 4 | Gutwerg Ori — SVP, GENERICS | Tax withholding (F): 1,775 @ $76.70 · Tax withholding (F): 1,888 @ $77.36 | EDGAR |
| 2026-02-17 | 4 | Lalwani Nikhil — PRESIDENT & CEO, Director | Tax withholding (F): 11,688 @ $76.70 · Tax withholding (F): 10,298 @ $77.36 | EDGAR |
| 2026-02-17 | 4 | CAREY STEPHEN P. — SVP & CFO | Tax withholding (F): 2,829 @ $76.70 · Tax withholding (F): 2,448 @ $77.36 | EDGAR |
Recent 8-K events — ANI PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ANIP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →